Table 2.

Gene-specific cfDNA advantage in the validation cohort.

Gene	n	cfDNA Advantage*	P-value	Recommendation
CALR	12	59.30%	0.009	Prioritize cfDNA
SF3B1	6	43.60%	0.031	Prioritize cfDNA
MPL	5	36.10%	0.063	cfDNA preferred
JAK2	62	11.90%	0.002	Consider cfDNA
ASXL1	10	15.70%	0.160	Consider cfDNA
TET2	11	-0.33%	0.960	Consider gDNA
DNMT3A	20	-2.80%	0.757	Consider gDNA

*cfDNA advantage calculated as mean VAF difference (cfDNA-gDNA)/gDNA.